An overview of the
current data from PsoProtectMe

Current Data

We are committed to sharing data and are delighted to provide open access to summary information from PsoProtectMe. These data are preliminary so should not be used to inform clinical decision making.

Click here to read our research paper detailing PsoProtect data. A summary can be found on the Psoriasis Association website here.

Our research paper detailing shielding behaviour can be found here. A summary can also be found on the Psoriasis Association website here.

Our research paper detailing factors associated with worsening of psoriasis in the pandemic can be found here. A summary can be found on the Psoriasis Association website here.

See our full list of research publications here.

0
PsoProtectMe surveys completed

Summary data from PsoProtectMe’s first 4791 participants.

Participants per country (≥10 participants):

Country Participants Country Participants
Argentina 226 Netherlands 38
Australia 39 Norway 24
Brazil 155 Panama 11
Canada 62 Paraguay 13
Chile 436 Peru 19
Denmark 51 Philippines 59
Dominican Republic 10 Poland 103
France 13 Portugal 204
Greece 14 Singapore 14
Hong Kong 18 South Africa 17
India 52 Spain 79
Ireland 61 Sweden 41
Italy 48 United Kingdom 2374
Japan 108 United States 329
Malaysia 11 Other (<10) 152
Mexico 10

Average age: 45 years (range 3-91)

Average BMI: 26.8 kg/m2

Type of psoriasis: 3950 plaque psoriasis, 1007 guttate psoriasis, 270 pustular psoriasis, 100 erythrodema

Gender:

Smoking status:

Coexisting psoriatic arthritis:

Type of psoriasis treatment:

Psoriasis severity change during the pandemic:

Have you been diagnosed with or thought you had COVID-19?

Did you go to hospital A&E due to your COVID-19?

Did you stay in hospital due to your COVID-19?

Has your COVID-19 infection got better?